Abstract
Background: Cardiovascular disease is largely explained by the traditional risk factors, but there are several novel risk factors that have been shown to predict cardiovascular morbidity. The measurement of low‐density lipoprotein particle size (LDLPS) is a novel cardiovascular risk factor, yet it is unknown whether this measurement provides additional information that may influence the subsequent medical treatment of patients.
Hypothesis: The measurement of LDLPS provides additional information that may influence preventive treatment for cardiovascular disease.
Methods: In an observational study of 82 patients referred to a tertiary care preventive cardiology clinic, LDLPS was dichotomized as either small or large and was determined by either the NMR LipoProfile test, the Vertical Auto Profile (VAP™) cholesterol test, or gradient gel electrophoresis. Lipid profiles were obtained and Framingham risk scores were calculated. Patients were stratified by Adult Treatment Panel guidelines as being at low, intermediate, or high risk.
Results: The study included 56 men and 26 women with a mean age of 54 ± 11 years. In the entire cohort of 82 patients, only 31 (38%) were at non‐high‐density lipoprotein (HDL) goal, only 21 (26%) were at goals for both non‐HDL and HDL, and only 18 (22%) were at goal for non‐HDL, HDL, and triglycerides. When considering each of the risk factor strata, 19 of 43 (44%) low‐risk patients were at non‐HDL goal and 12 of these also had a small LDLPS. Only 8 of 18 (44%) intermediate‐risk patients were at non‐HDL goal and 7 of these (88%) had small LDLPS. Finally, only four high‐risk patients were at non‐HDL goal and three of these (75%) had small LDLPS.
Conclusions: Knowing the LDLPS could alter subsequent therapeutic recommendations for most patients who have reached target lipid values.
Keywords: lipids, risk factors, cardiovascular disease, screening
Full Text
The Full Text of this article is available as a PDF (27.5 KB).
References
- 1. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, McQueen M, Budaj A, Pais P, Varigos J, Lisheng L: Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTER‐HEART study): Case‐control study. Lancet 2004; 364: 952–962 [DOI] [PubMed] [Google Scholar]
- 2. Greenland P, Knoll MD, Stamler J, Neaton JD, Dyer AR, Garside DB, Wilson PW: Major risk factors as antecendents of fatal and nonfatal coronary heart disease events. J Am Med Assoc 2003; 290: 891–897 [DOI] [PubMed] [Google Scholar]
- 3. Grundy SM, Pasternak R, Greenland P, Smith S Jr, Fuster V: Assessment of cardiovascular risk by use of multiple‐risk‐factor assessment equations. A statement for healthcare professionals from the American Heart Association and the American College of Cardiology. J Am Coll Cardiol 1999; 34: 1348–1359 [DOI] [PubMed] [Google Scholar]
- 4. Greenland P, Smith SC, Grundy SM: Improving coronary heart disease risk assessment in asymptomatic people. Role of traditional risk factors and non‐invasive cardiovascular tests. Circulation 2001; 104; 1863–1867 [DOI] [PubMed] [Google Scholar]
- 5. Ridker PM, Brown NJ, Vaughan DE, Harrison DG, Mehta JL: Established and emerging plasma biomarkers in the prediction of first atherothrombotic events. Circulation 2004; 109 (suppl IV): IV6–IV19 [DOI] [PubMed] [Google Scholar]
- 6. Bard RL, Kalsi H, Rubenfire M, Wakefield T, Fex B, Rajagopalan S, Brook RD: Effect of carotid atherosclerosis screening on risk stratification during primary cardiovascular disease prevention. Am J Cardiol 2004; 93: 1030–1032 [DOI] [PubMed] [Google Scholar]
- 7. Bard RL, Rubenfire M, Eagle K, Clarke NS, Brook RD: Utility of C‐reactive protein measurement in risk stratification during primary cardiovascular disease prevention. Am J Cardiol 2005; 95: 1378–1379 [DOI] [PubMed] [Google Scholar]
- 8. http://www.liposcience.com/(accessed April 4, 2005).
- 9. http://www.atherotech.com/ (accessed April 4, 2005).
- 10. http://www.berkeleyheartlab.com/ (accessed April 4, 2005).
- 11. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment on High Blood Cholesterol in Adults (Adult Treatment Panel III). J Am Med Assoc 2001; 285: 2486–2509 [DOI] [PubMed] [Google Scholar]
- 12. Lamarche B, Tchernof A, Moorjani S, Prud'homme D, Nadeau A, Tremblay A, Lupien PJ, Bouchard C, Despres JP: Small, dense LDL particles as a predictor of the risk of ischemic heart disease in men: Prospective results from the Quebec Cardiovascular Study. Circulation 1997; 95: 69–75 [DOI] [PubMed] [Google Scholar]
- 13. St‐Pierre AC, Ruel IL, Cantin B, Dagenais GR, Bernard PM, Despres JP, Lamarche B: Comparison of various electrophoretic characteristics of LDL particles and their relationship to the risk of ischemic heart disease. Circulation 2001; 104: 2295–2299 [DOI] [PubMed] [Google Scholar]
- 14. St‐Pierre AC, Cantin B, Dagenais GR, Mauriège P, Bernard PM, Després JP, Lamarche B: Low‐density lipoprotein subfractions and the long‐term risk of ischemic heart disease in men. 13‐year follow‐up data from the Quebec Cardiovascular Study. Arterioscler Thromb Vasc Biol 2005; 25: 553–559 [DOI] [PubMed] [Google Scholar]
- 15. Campos H, Moyé LA, Glasser SP, Stampfer MJ, Sacks FM: Low‐density lipoprotein size, pravastatin treatment, and coronary events. J Am Med Assoc 2001; 286: 1468–1474 [DOI] [PubMed] [Google Scholar]
- 16. Rajman I, Eacho PI, Chowienczyk PJ, Ritter JM: LDL particle size: An important drug target? Br J Clin Pharmacol 1999; 48: 125–133 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17. Stampfer MJ, Krauss RM, Ma J, Blanche PJ, Holl LG, Sacks FM, Hennekens CH: A prospective study of TG level, LDL particle diameter, and risk of myocardial infarction. J Am Med Assoc 1996; 276: 882–888 [PubMed] [Google Scholar]
- 18. Gardner CD, Fortmann SP, Krauss RM: Association of small LDL particles with the incidence of CAD in men and women. J Am Med Assoc 1996; 276: 875–881 [PubMed] [Google Scholar]
- 19. Otvos JD, Jeyarajah EJ, Cromwell WC: Measurement issues related to lipoprotein heterogeneity. Am J Cardiol 2002; 90 (suppl): 22i–29i [DOI] [PubMed] [Google Scholar]
- 20. Ford ES, Giles WH, Dietz WH: Prevalence of the metabolic syndrome among US adults. Findings from the Third National Health and Nutrition Examination Survey. J Am Med Assoc 2002; 287: 356–359 [DOI] [PubMed] [Google Scholar]
- 21. Ford ES, Mokdad AH, Giles WH: Serum total cholesterol concentrations and awareness, treatment, and control of hypercholesterolemia among US adults. Findings from the National Health and Nutrition Examination Survey, 1999‐2000. Circulation 2003; 107: 2185–2189 [DOI] [PubMed] [Google Scholar]